Zobrazeno 1 - 10
of 69
pro vyhledávání: '"Ian A. J. Lorimer"'
Publikováno v:
Scientific Reports, Vol 7, Iss 1, Pp 1-14 (2017)
Abstract Glioblastoma is the most common type of adult brain tumour and has a median survival after diagnosis of a little more than a year. Glioblastomas have a high frequency of mutations in the TERT promoter and CDKN2A locus that are expected to re
Externí odkaz:
https://doaj.org/article/9600ca8f6ee94a838aaa5c94ff55151b
Autor:
Aparna Ramanathan, Ian A. J. Lorimer
Publikováno v:
Cancer Gene Therapy. 29:156-166
In spite of significant recent advances in our understanding of the genetics and cell biology of glioblastoma, to date, this has not led to improved treatments for this cancer. In addition to small molecule, antibody, and engineered virus approaches,
Autor:
Alexander Gont, Danny Jomaa, Karen Jardine, Ian A. J. Lorimer, Sylvie J. Lavictoire, David P. Cook
Publikováno v:
The Journal of Biological Chemistry
The protein Lgl1 is a key regulator of cell polarity. We previously showed that Lgl1 is inactivated by hyperphosphorylation in glioblastoma as a consequence of PTEN tumour suppressor loss and aberrant activation of the PI 3-kinase pathway; this contr
Autor:
Ian A. J. Lorimer
Publikováno v:
Small GTPases
Glioblastoma is an aggressive and incurable form of brain cancer. Both mutation analysis in human glioblastoma and mouse modelling studies have shown that aberrant activation of the PI 3-kinase pathway is a central driver of glioblastoma malignancy.
Autor:
Gerard H. Jansen, Katy Milne, Francois Jacques, B Erik Apedaile, Jasmine Prevost, Nathalie Dumais, John Woulfe, Brad H. Nelson, Garth Nicholas, Victorine Sikati Foko, Ian A. J. Lorimer
Publikováno v:
Neuro-oncology Advances
BackgroundGlioblastoma (GBM) is known to use both local and systemic immunosuppressive strategies. One such strategy is the expression of the immune checkpoint protein programmed cell death ligand-1 (PD-L1) by both tumor cells and tumor-associated im
Autor:
Danny Jomaa, Karen Jardine, Sylvie J. Lavictoire, Ian A. J. Lorimer, David P. Cook, Alexander Gont
The protein Lgl1 has key roles in the regulation of cell polarity. We have shown that Lgl1 is inactivated by hyperphosphorylation in glioblastoma as a consequence of PTEN loss and aberrant activation of the PI 3-kinase pathway; this contributes to gl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e208ae389a78934c9d03d519c3cdd4a2
https://doi.org/10.1101/2020.12.01.406538
https://doi.org/10.1101/2020.12.01.406538
Publikováno v:
Neuro Oncol
Virtually all primary glioblastomas have aberrant activation of the PI 3-kinase pathway through mutational inactivation of tumour suppressors such as PTEN and/or mutational activation of oncogenes. Most glioblastomas also overexpress the Rac guanine
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e58fbf7fa7b1aff836443145562a44d2
https://europepmc.org/articles/PMC6847169/
https://europepmc.org/articles/PMC6847169/
Autor:
Douglas A. Gray, Ian A. J. Lorimer, Caitlyn Vlasschaert, Lisa M. Julian, William L. Stanford, Alexander Gont, Sylvie J. Lavictoire, Danny Jomaa
Publikováno v:
Molecular Therapy. Methods & Clinical Development
Molecular Therapy: Methods & Clinical Development, Vol 9, Iss, Pp 12-22 (2018)
Molecular Therapy: Methods & Clinical Development, Vol 9, Iss, Pp 12-22 (2018)
The tumor suppressor PTEN is frequently inactivated in glioblastoma. PTEN-L is a long form of PTEN produced by translation from an alternate upstream start codon. Unlike PTEN, PTEN-L has a signal sequence and a tract of six arginine residues that all
Autor:
Carole J Proctor, Ian A J Lorimer
Publikováno v:
PLoS ONE, Vol 6, Iss 7, p e22038 (2011)
Neurodegeneration is an age-related disorder which is characterised by the accumulation of aggregated protein and neuronal cell death. There are many different neurodegenerative diseases which are classified according to the specific proteins involve
Externí odkaz:
https://doaj.org/article/4e64a6a62b90439781a547aaec98936b
Autor:
Ian A. J. Lorimer, Ritesh Kumar
INTRODUCTION: Glioblastoma (GBM) is the most common adult primary brain tumour. Despite maximal therapy, median survival is 14 months. Resistance to therapy in GBM is due to extensive molecular heterogeneity. Gene expression profiling demonstrates fo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4747d1d7e338182d98dd28ec10ce8fda
https://europepmc.org/articles/PMC6216555/
https://europepmc.org/articles/PMC6216555/